Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.63 |
| ▸ | GABRD | O14764 | 2/20 | 0.63 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.63 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.63 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.63 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.63 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.63 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.63 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.63 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.63 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.63 |
| ▸ | GABRE | P78334 | 2/20 | 0.63 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.63 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.63 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.63 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.63 |
| ▸ | LDHA | P00338 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31043801 | 0.81 | GABRP (0.66) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1436086 | 0.81 | GABRP (0.66) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9508554 | 0.79 | GABRP (0.63) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL19857491 | 0.79 | GABRP (0.63) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL915144 | 0.78 | ALDH1A1 (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1390714 | 0.78 | GABRP (0.61) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2013192 | 0.78 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3752864 | 0.78 | GABRP (0.61) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30962313 | 0.78 | GABRP (0.61) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL14687807 | 0.78 | GABRP (0.61) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2875005-B1 | N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS INC (CN) | 2020-11-11 | — | — | EP | disclosed |
| US-10676468-B2 | N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2020-06-09 | — | — | US | disclosed |
| US-20150191460-A1 | N-(3-heteroarylaryl)-4-arylarylcarboxamides and Analogs as Hedgehog Pathway Inhibitors and Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2015-07-09 | — | — | US | disclosed |
| EP-2875005-A1 | N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF | Impact Therapeutics, Inc. (CN) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014012511-A1 | N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS, INC. (CN) | 2014-01-23 | — | — | WO | disclosed |
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | BERGMANIS ARIJA A | 2005-11-17 | — | — | US | disclosed |
| US-6956052-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2005-10-18 | — | — | US | disclosed |
| EP-1501805-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1444207-A2 | SUBSTITUTED PYRAZOLYL-COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040110741-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORARTION | 2004-06-10 | — | — | US | disclosed |
| WO-2003095430-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003024935-A2 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676468-B2 | N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof | SHH, GLI1, SMO | GABRP 4238/4885GABRD 3060/4885GABRA1 3536/4885 |
| US-20040110741-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | GABRP 4263/4885GABRD 4299/4885GABRA1 4273/4885 |
| US-20150191460-A1 | N-(3-heteroarylaryl)-4-arylarylcarboxamides and Analogs as Hedgehog Pathway Inhibitors and Use Thereof | SHH, GLI1, SMO | GABRP 4238/4885GABRD 3060/4885GABRA1 3536/4885 |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | GABRP 4263/4885GABRD 4299/4885GABRA1 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.